<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">global-journal-of-medical-research-f-diseases</journal-id>
<journal-title-group>
<journal-title>Global Journal of Medical Research - F: Diseases</journal-title>
</journal-title-group>
<issn publication-format="print">0975-5888</issn>
<issn publication-format="electronic">2249-4618</issn>
<publisher><publisher-name>Global Journals Publishing Group Incorporated</publisher-name></publisher>
<self-uri xlink:href="https://globaljournals.org/journal-seo-export/jats/60705.xml" />
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">60705</article-id>
<title-group>
<article-title>Considerations Necessary Regarding Prostate Cancer with the Options of Surgical Removal of the Prostate Gland or with Androgen Deprivation (Aka Testosterone Inactivating) Therapy (ADT) as Follow-on or Primary Treatment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Maack</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff1" />
</contrib>
</contrib-group>
<aff id="aff1">UNITED STATES</aff>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2019-01-15">
<day>15</day>
<month>01</month>
<year>2019</year>
</pub-date>
<volume>19</volume>
<issue>F4</issue>
<fpage>1</fpage>
<lpage>2</lpage>
<abstract><p>Abstract not found</p></abstract>
<self-uri content-type="pdf" xlink:href="https://globaljournals.org/GJMR_Volume19/1-Considerations-Necessary-Regarding-Prostate.pdf" />
<self-uri content-type="html" xlink:href="https://globaljournals.org/scholarly-articles/considerations-necessary-regarding-prostate-cancer-with-the-options-of-surgical-removal-of-the-prostate-gland-or-with-androgen-deprivation-aka-testosterone-inactivating-therapy-adt-as-follow-on-or/" />
</article-meta>
</front>
<body>
<sec>
<title>Full Text</title>
<p>Charles (Chuck) Maack (ECaP) â€“ Prostate Cancer continuing patient since 1992, Advocate, Activist, and Mentor to Men so diagnosed and their Caregivers online Worldwide With surgical removal of a cancerous prostate gland, PSA nadir should drop to near total absence well into the ultrasensitive testing level below 0.5ng/ml.  If this is not achieved, it is likely all cancer cell activity has not been removed, and further treatment is necessary.   A variety of tests should be performed for baseline markers among which should be free Testosterone to determine level as well as any bone issues; deoxypyridinoline (DpD) urine test to determine bone resorption; prolactin level since if high could inhibit ADT therapy as well as cause several other issues    (See: https://tinyurl.com/7w5omeo); lipid or fatty acid profile since both de novo and dietary lipids seem to be important contributors to prostate cancer growth and development; inflammation markers since inflammation may drive resistance to androgen deprivation therapy (ADT); and any other markers to aid in determining the best strategy for treatment.</p>
</sec>
</body>
</article>